Get started
Author

Luis Felipe Casado

Observed names: L F Casado, L. F. Casado, L. Felipe Casado, L.F. Casado, Luis F Casado, Luis F. Casado, Luis Felipe Casado Montero, Luis-Felipe Casado, Luis‐Felipe Casado, Luís Felipe Casado
Observed institutions: Hospital Virgen de la Salud, HM Hospitales, Hospital Universitario HM Sanchinarro, Complejo Hospitalario Universitario de Toledo, Weber, Hospital Universitario de Toledo, University of Castilla-La Mancha
ORCID: 0000-0002-8171-0674
Observed ORCID: 0000-0002-8171-0674
OpenAlex ID: A5030093787
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
2016 · J L Steegmann, M Baccarani, et al. · Leukemia · 495
PDF
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
2019 · Laura Rosiñol, Albert Oriol, et al. · Blood · 232
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
2025 · Jane F. Apperley, Dragana Milojkovic, et al. · Leukemia · 206
PDF
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
2016 · V S Hoffmann, M Baccarani, et al. · Leukemia · 106
PDF
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
2020 · Joaquín Martínez-López, María-Victoria Mateos, et al. · Blood Cancer Journal · 81
PDF
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
2023 · Laura Rosiñol, Albert Oriol, et al. · Blood · 69
PDF
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
2022 · Meletios A Dimopoulos, Paul G Richardson, et al. · The Lancet Haematology · 51
PDF
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
2018 · Juan Carlos Hernández-Boluda, Arturo Pereira, et al. · Blood Cancer Journal · 48
Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT
2023 · Ana Jiménez-Ubieto, María Poza, et al. · Leukemia · 44
PDF
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
2022 · A. Luna, L. Pérez-Lamas, et al. · Annals of Hematology · 41
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
2024 · Annamaria Brioli, Elza Lomaia, et al. · Leukemia · 37
PDF
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
2023 · Lucía Pérez-Lamas, Alejandro Luna, et al. · Cancers · 37
PDF
Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines
2016 · María Luisa Lozano, N. Revilla, et al. · Annals of Hematology · 31
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2025 · Wojciech Jurczak, Michal Kwiatek, et al. · Journal of Clinical Oncology · 25
PDF
Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation
2001 · Alfonso Verdú, Marı́a R Cazorla, et al. · Pediatric Neurology · 22
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
2024 · Marta Lasa, Laura Notarfranchi, et al. · Journal of Clinical Oncology · 20
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab
2011 · Carlos Vallejo, Eduardo Ríos, et al. · Expert Review of Hematology · 17
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
2022 · Ricardo Sánchez, Sara Dorado, et al. · Scientific Reports · 16
PDF
Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients
2019 · Beatriz Colom-Fernández, Anna Kreutzman, et al. · Frontiers in Pharmacology · 16
Cost‐utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
2017 · Luis Felipe Casado, José Ángel Hernández, et al. · European Journal Of Haematology · 16
PDF
High expression of the ILT2 (LIR-1) inhibitory receptor for major histocompatibility complex class I molecules on clonal expansions of T large granular lymphocytes in asymptomatic patients.
2001 · L F Casado, E Granados, et al. · PubMed · 15
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
2016 · Carlos Rubio-Terrés, Luis Felipe Casado, et al. · ClinicoEconomics and Outcomes Research · 14
PDF
Prenatal stroke in a neonate heterozygous for factor V Leiden mutation
2004 · Alfonso Verdu, María R. Cazorla, et al. · Brain and Development · 14
Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)
2015 · M. Dimopoulos, S. Lonial, et al. · Clinical Lymphoma Myeloma & Leukemia · 11
Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica
2011 · Luis Felipe Casado, José Antonio García Marco, et al. · Gaceta Sanitaria · 10
Works count: 61
Citation count: 1,758
H-index: 17
I10-index: 25
Year
Topic
Type